Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.
about
Monoclonal antibodies targeting CD38 in hematological malignancies and beyondCD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemiaA biophysical model of cell adhesion mediated by immunoadhesin drugs and antibodiesEffect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody capHerceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis.Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.Antibody constructs for radioimmunodiagnosis and treatment of human pancreatic cancer.HER2/neu antisense targeting of human breast carcinoma.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.LSPR Biosensor Signal Enhancement Using Nanoparticle-Antibody Conjugates.The evolving role of monoclonal antibodies and dendritic cell therapy in hematologic malignancies.Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric NanomedicinesCellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.Self-assembled antibody multimers through peptide nucleic acid conjugation.A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.α-Helical coiled-coil peptide materials for biomedical applications.In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate.Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.Engineering therapeutic monoclonal antibodies.
P2860
Q26766718-C0767D55-3AA6-432E-B8B6-EB71A10384EEQ28146150-C5350938-B717-4DE1-A965-E8BE9D6337EFQ28478230-2FECFB7C-30BC-4090-8325-EFC91F1F446AQ33392541-9319EA76-550F-4B75-BECD-053E4529886BQ33985565-43C347D3-2C68-46E9-99A6-0D2EC6F8D186Q33997021-9AA1A807-33A4-4F9F-8F9E-4787FFA66D21Q34102657-D9C17EE9-D272-4F37-997F-FDAAA906C119Q34116897-FA9D10FE-E531-47D7-97F5-46A8D350972FQ34130563-76EC21B1-15E3-4B63-9971-2D317C6CA987Q34451956-7C7D8CB7-4913-4DA8-9054-95DCB119C404Q34988055-39AF2578-D016-43E1-90DF-42F366792751Q35030067-55031605-42B6-4A15-97F5-4C1A4766ED5FQ35173179-0EF79BA7-BCDD-432C-990B-60CFBB9A8F78Q35861726-550C165B-AE02-4ADF-9124-00CC93B08C8CQ36079223-72C93334-2F4A-45CF-A842-846F0AEEA8C0Q36216376-75125692-2A44-43F9-B830-818025BE9EDEQ36512143-AD86C1D1-B815-4860-AD66-9896E8978CD7Q37633102-06B3C96D-45FF-49D5-8B0E-ADDD04970C55Q38850042-CF44AC11-3D38-49FF-869A-8A2E7999395BQ38946939-909CAC8C-606B-4443-8E1C-E939DECE50CEQ38997358-8A6946D4-6BE3-4942-BF6E-1F1B4A7594A2Q39650162-ED893BC3-696A-46A8-A1A4-464E00C7E118Q39674450-095CF8A1-7233-4E90-A6B6-95B51C8D3D52Q40054666-49CBB8E0-7EE0-4F22-9BDF-CE1D1E8AD0D4Q41910884-5B62B49D-7D8F-4EB6-9BCC-1996DD165860Q47820029-8FC4F5E8-6802-4819-BD2A-B44762845F35
P2860
Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Homodimerization of tumor-reac ...... t or apoptosis of tumor cells.
@ast
Homodimerization of tumor-reac ...... t or apoptosis of tumor cells.
@en
type
label
Homodimerization of tumor-reac ...... t or apoptosis of tumor cells.
@ast
Homodimerization of tumor-reac ...... t or apoptosis of tumor cells.
@en
prefLabel
Homodimerization of tumor-reac ...... t or apoptosis of tumor cells.
@ast
Homodimerization of tumor-reac ...... t or apoptosis of tumor cells.
@en
P2093
P2860
P356
P1476
Homodimerization of tumor-reac ...... t or apoptosis of tumor cells.
@en
P2093
P2860
P304
P356
10.1073/PNAS.94.14.7509
P407
P577
1997-07-01T00:00:00Z